In addition, we found that blockade of BTLA signaling increased IFN-γ production in both circulating CD4+ and CD8+ T cells isolated from HCC patients (Figure 4), which strengthens the emerging notion that BTLA can be used as a target of cancer immunotherapy [42]. Here, CD8A is linked to cancer.